Archive for the ‘Regenerative Medicine’ Category

Mathew Vincent of ACT on hESC derived RPE cells - at Stem Cells USA RM Congress 2012
Mathew Vincent, Director of Business Development at Advanced Cell Technology, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Meaningful clinical results with hESC derived RPE cells in patients with SMD and Dry AMD. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:25:03More inScience Technology

Continued here:
Mathew Vincent of ACT on hESC derived RPE cells - at Stem Cells USA

Robert Hariri of Lifebank USA on cord blood and RM space - at World Cord Blood Congress 2012
Dr. Robert Hariri, President of Lifebank USA spoke at the World Cord Blood Congress 2012 on the topic, #39;Increasing cord blood presence in the regenerative medicine space. #39; World Cord Blood Congress is where private and public cord blood banks, pharma and biotechs, academia and government come to debate advances in cord blood banking and therapeutics. For more information, go to http://www.terrapinn.com/cordblood. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:24:11More inScience Technology

Original post:
Robert Hariri of Lifebank USA on cord blood and RM space - at World Cord Blood Congress 2012 - Video

PhD training programme
Stem cells regenerative medicine is an exciting and fast moving field that brings together experts in biology, medicine, chemistry, engineering and other areas to find solutions to some of the most challenging scientific and medical problems we face today. The MRC Centre for Regenerative Medicine at the University of Edinburgh offers an integrated and structured PhD training programme in stem cells and regenerative medicine, incorporating taught and research elements to provide high-level training in theoretical and practical stem cell research. More info: http://www.crm.ed.ac.ukFrom:CRMedinburghViews:5 0ratingsTime:01:56More inPeople Blogs

Follow this link:
PhD training programme - Video

SU2C-CRI Cancer Immunology Translational Research Dream Team
Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) announce the formation of a Dream Team project dedicated to cancer immunology mdash; "Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy." Cancer immunology is a field of research that explores the complex relationship between cancer and the immune system, with the goal of discovering immune-based solutions to curing cancer. The SU2C-CRI Cancer Immunology Translational Research Dream Team will receive $10 million in funding over three years for this translational cancer research project that will unite laboratory and clinical efforts leading to the immunological treatment, control and prevention of cancer. The team will be led by James P. Allison, Ph.D., and Antoni Ribas, MD, Ph.D. Allison is chairman of the department of immunology, director of the immunotherapy platform and co-director of the David H. Koch Center for Applied Research of Genitourinary Cancers at The University of Texas MD Anderson Cancer Center. Ribas is professor of medicine, surgery and molecular and medical pharmacology, director of the tumor immunology program area at the Jonsson Comprehensive Cancer Center, and member of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles (UCLA). "The goal of our Dream Team is to expand, optimize and explore combinations of two novel immunotherapies, immune checkpoint blockade and adoptive T-cell transfer ...From:CancerResearchInstViews:14 2ratingsTime:03:37More inNonprofits Activism

See the article here:
SU2C-CRI Cancer Immunology Translational Research Dream Team - Video

Passfail.com News: Harvard Bioscience Announces Filing of IPO Registration Stat...
Harvard Bioscience (HBIO), a global developer, manufacturer and marketer of a broad range of tools to advance life science research and regenerative medicine, announced that its wholly-owned subsidiary, Harvard Apparatus Regenerative Technology, Inc., filed a registration statement with the SEC for an initial public offering, or IPO, of Harvard Apparatus Regenerative Technology #39;s common stock. Following the IPO, Harvard Apparatus Regenerative Technology will own Harvard Bioscience #39;s regenerative medicine device business, which develops life-saving medical devices in the field of regenerative medicine, including devices to be used by physicians for growing organs outside the body for transplant. Following the IPO, Harvard Bioscience will own at least 80% of Harvard Apparatus Regenerative Technology #39;s common stock. Harvard Bioscience intends to distribute its remaining interest in Harvard Apparatus Regenerative Technology to Harvard Bioscience #39;s shareholders in a pro-rata, tax-free dividend approximately 120 days following the closing of the IPO. Summer Street Research Partners will act as sole book-running manager for the offering. This is Sayoko Murase for Passfail.com, taking you behind the ticker. For Passfail.com, Behind The Ticker (TM) Pass Fail NewsFrom:passfailtvViews:0 0ratingsTime:01:15More inNews Politics

Visit link:
Passfail.com News: Harvard Bioscience Announces Filing of IPO Registration Stat... - Video

BioLife Solutions Inc: Ticker Symbol BLFS
investorials.com BioLife Solutions Inc., ticker symbol BLFS, is a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, as well as a contract aseptic media manufacturer. The company #39;s three product lines help regenerative medicine, drug discovery and bio-banking companies reduce cell damage and death during transportation and while in storage. The company also owns and operates a contract manufacturing business that has generated significant revenues and helped reduced its own manufacturing costs. To learn more about BioLife Solutions, visit their Investorial at www dot Investorials dot com slash companies slash BLFS.From:InvestorialsViews:0 0ratingsTime:00:55More inEducation

Follow this link:
BioLife Solutions Inc: Ticker Symbol BLFS - Video

Regenerative Medicine Center Lebanon
We promise to ensure cell-therapy based applications in a safe and innovative way. We place the highest priority on our commitment to practicing medicine in a way that constantly delivers the safest care possible to every patient.From:revivamedicalViews:0 0ratingsTime:13:59More inPeople Blogs

Read more:
Regenerative Medicine Center Lebanon - Video

Regenerative Medicine Center, Reviva Lebanon.
Our mission is to bring scientific innovation to patients seeking a trace of hope in new medicine therapy through cellular enhancement and medical excellence. We aim to be recognized as an all-in-one leader center in stem cell and regenerative medicine research and applications in the MENA region.From:revivamedicalViews:0 0ratingsTime:05:59More inPeople Blogs

More here:
Regenerative Medicine Center, Reviva Lebanon. - Video

Shawn Chavez, PhD, talks about research on selecting healthy embryos for IVF
During in-vitro fertilization (IVF), physicians much choose among many embryos to pick the ones that are most likely to produce a successful pregnancy and health child. Shawn Chavez, PhD, a researcher at the Stanford Institute for Stem Cell Biology and Regenerative Medicine, talks about an automated time-lapse recording system that can accurately detect which embryos are healthiest. She discusses new research showing that a parameter called "fragmentation" is important.From:institutesofmedicineViews:3 0ratingsTime:02:05More inEducation

Originally posted here:
Shawn Chavez, PhD, talks about research on selecting healthy embryos for IVF - Video

Blond McIndoe Research Foundation -Burns Charity
Blond McIndoe Research Foundation (BMRF) is a charity, which has spent over 50 years pioneering research into wound healing and regenerative medicine to help burns survivors, and patients with soft tissue injuries. Our aim is to develop new procedures and technologies that will simplify treatments, reduce healing time and reduce scarring left by their injuriesFrom:Blond McIndoeViews:1 0ratingsTime:06:09More inNonprofits Activism

Original post:
Blond McIndoe Research Foundation -Burns Charity - Video

"Update from the California Institute for Regenerative Medicine" - Dr. Jonathan Thomas
Dr. Thomas is Chairman of the Independent Citizens Oversight Committee at CIRM and works extensively with patient advocates.From:unite2fightparalysisViews:0 0ratingsTime:30:28More inNonprofits Activism

Read this article:
"Update from the California Institute for Regenerative Medicine" - Dr. Jonathan Thomas - Video

World Stem Cell Summit - Terzic
The World Stem Cell Summit, December 3-5 in West Palm Beach, Fla. unites internationally renowned scientists, clinicians, students, policymakers, regulators, patient advocates, and philanthropists to share knowledge and advance collaborations in the stem cell and regenerative medicine community. The meeting includes in-depth programming and more than 150 renowned international speakers. In this video, Dr. Andre Terzic, director of the Mayo Clinic Center for Regenerative Medicine addresses the importance of the summit and the emerging field of regenerative medicine.From:mayoclinicViews:6 0ratingsTime:05:34More inScience Technology

Read the original here:
World Stem Cell Summit - Terzic - Video

The World Stem Cell Summit - Dr. Yaszemski
The World Stem Cell Summit, December 3-5 in West Palm Beach, Fla. unites internationally renowned scientists, clinicians, students, policymakers, regulators, patient advocates, and philanthropists to share knowledge and advance collaborations in the stem cell and regenerative medicine community. The meeting includes in-depth programming and more than 150 renowned international speakers, including leaders from Mayo Clinic #39;s Center for Regenerative Medicine. Among them is Mayo Clinic Dr. Michael Yaszemski. In this video he talks about the summit, the emerging field of regenerative medicine and his unique military perspective.From:mayoclinicViews:5 1ratingsTime:04:16More inScience Technology

See original here:
The World Stem Cell Summit - Dr. Yaszemski - Video

World Stem Cell Summit - Windebank
The World Stem Cell Summit, December 3-5 in West Palm Beach, Fla. unites internationally renowned scientists, clinicians, students, policymakers, regulators, patient advocates, and philanthropists to share knowledge and advance collaborations in the stem cell and regenerative medicine community. The meeting includes in-depth programming and more than 150 renowned international speakers, including leaders from Mayo Clinic #39;s Center for Regenerative Medicine. In this video, Dr. Anthony Windebank talks about the emerging field of regenerative medicine.From:mayoclinicViews:8 0ratingsTime:03:39More inScience Technology

Read the original here:
World Stem Cell Summit - Windebank - Video

TEDxSalford - Sir Ian Wilmut - From Dolly to Curing Human Disease
Sir Ian Wilmut is a world-renowned embryologist and specialist in regenerative medicine. He is best known as the man who led the team that in 1996 first cloned a mammal, a Finn Dorset lamb named "Dolly". Dolly was the first ever clone derived from an adult cell. The research resulting in Dolly #39;s birth stemmed from efforts to genetically engineer sheep and cows in order that their milk would contain human proteins with medicinal properties, such as human antibodies. More recently he was the founding Director of the Centre for Regenerative Medicine in the University of Edinburgh. The Mission of this rapidly expanding Centre is to develop new treatments for human disease through innovative research with stem cells. The new Centre covers the full spectrum of research -- from basic mechanisms of stem cell biology, to clinical trials with stem cells and their derivatives. The aim of his own research is to be able to produce human cells for use in research and in future for treatment of diseases, such as motor Neuron Disease. In his talk he will describe the way in which the cloning research has provided revolutionary new opportunities in regenerative medicine. Credits: Camerawork: Nathan Rae Team - nathanrae.co.uk Post production: Elliott Wragg - twitter.com Audio restoration : Jorge Polvorinos - jorgepolvorinos.wordpress.com Heat of IT and Design Vlad Victor Jiman - twitter.comFrom:TEDxTalksViews:5 1ratingsTime:19:27More inNonprofits Activism

Continue reading here:
TEDxSalford - Sir Ian Wilmut - From Dolly to Curing Human Disease - Video

Presentation- Mayo Clinic, Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome
Nearly 2000 infants are born each year with Hypoplastic Left Heart Syndrome and require immediate surgical intervention -- these children remain at risk for a heart transplant throughout their lives. The Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome (HLHS) is a purpose-driven operation forged within an academic medical environment that is designed to accelerate idealism into practice. This entity emerged out of the innovative spirit of Mayo Clinic, dedicated participation of HLHS patients and families, and the focused milestone-based vision of its philanthropic partner. The principle objective of the program is to delay or prevent heart transplant by applying functional regenerative strategies for children with HLHS. Presented by: Timothy J. Nelson, MD, PhD Director of Regenerative Medicine Consult Service, Transplant Center, Director of the Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome, Mayo Clinic Mindy Rice Program Manager, Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome, Mayo ClinicFrom:FasterCuresViews:4 0ratingsTime:28:28More inNonprofits Activism

View post:
Presentation- Mayo Clinic, Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome - Video

SCMOM 2012_Equalix
Eqalix has received exclusive commercial licensing rights from three prominent institutions for several groundbreaking technologies in Regenerative Medicine which have the potential to revolutionize the unmet needs in multiple commercial and therapeutic applications. These technologies introduce the second generation of products into development and address previously unmet medical needs in the Regenerative Medicine space. Using these technologies, Eqalix plans to develop and commercialize (a) plant-protein based nano-fiber scaffold for use in wound healing and aesthetic dermatology; (b) small-diameter hybrid vessels that foster the creation of a functional endothelium (c) 3-Dimensional tissue scaffolds with adjustable properties for organ and tissue replacement and repair. http://www.eqalix.com Presenter: Joseph Connell, CEO, EqalixFrom:AllianceRegenMedViews:0 0ratingsTime:16:47More inScience Technology

View post:
SCMOM 2012_Equalix - Video

SCMOM 2012_ViaCyte
ViaCyte, Inc., a leader in the emerging field of regenerative medicine, is headquartered in San Diego, California. ViaCyte #39;s innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors (PEC-01), with subcutaneous implantation in a retrievable and immune-isolating encapsulation medical device. Once implanted, the precursor cells mature into endocrine cells that secrete insulin in a regulated manner to control blood glucose levels. ViaCyte #39;s goal is a product that can free Type 1 and 2 diabetic patients from long-term insulin dependence. ViaCyte has received substantial financial support from both CIRM and JDRF. http://www.viacyte.com Presenter: Paul Laikind, President and CEO, ViaCyteFrom:AllianceRegenMedViews:5 1ratingsTime:16:42More inScience Technology

Visit link:
SCMOM 2012_ViaCyte - Video

SCMOM 2012_MaxCyte
MaxCyte is the leader in scalable and clinical cell transfection, bringing to market its patented flow electroporation technology. MaxCyte is applying its significant capabilities in the discovery, development, and manufacturing of virtually all classes of innovative therapeutics targeting a broad range of diseases. MaxCyte #39;s customers and partners utilize its technologies in the development and commercialization of cell-based therapies in regenerative medicine and active cell immunotherapies and in the discovery and development of protein drugs, monoclonal antibodies, vaccines, and small molecule drugs. This clinical-grade cell loading technology is fully developed, well validated and has received MF designation with CBER at US FDA. http://www.maxcyte.com Presenter: Douglas Doerfler, President and CEO, MaxCyteFrom:AllianceRegenMedViews:2 1ratingsTime:13:14More inScience Technology

Read more:
SCMOM 2012_MaxCyte - Video

SCMOM 2012_Ensuring Maximum Reimbursement for a Regen Med Product
How to ensure that your regenerative medicine product is appropriately reimbursed is an increasingly difficult task for company executives. Thriving in both the private insurance and Medicare markets requires careful and long-range planning. Using a case-study approach, these panelists will discuss reimbursement challenges, goals, and strategies. They will discuss how to get products covered and reimbursed by payers in an environment that demands cost effectiveness and value.From:AllianceRegenMedViews:7 0ratingsTime:58:34More inScience Technology

Follow this link:
SCMOM 2012_Ensuring Maximum Reimbursement for a Regen Med Product - Video

SCMOM 2012_The Regen Med Investment Hypothesis
This session will examine the regenerative medicine investment hypothesis from the perspective of the primary sources of capital at key stages in the development process from discovery to late-stage clinical development. Additionally, panelists will discuss different parts of the sector -- therapeutics, devices, tools, and services - and different types of business models to explore how they evaluate risk and why some models are more compelling than others. Investor perspectives represented on the panel will include traditional venture, angels, institutional investors and corporate strategics.From:AllianceRegenMedViews:3 0ratingsTime:56:18More inScience Technology

Read the original here:
SCMOM 2012_The Regen Med Investment Hypothesis - Video

Stem Cells 101 - Mayo Clinic
Stem cells and their use in regenerative medicine have been in the media a lot lately. But, what exactly does it mean? Physicians and researchers in the Center for Regenerative Medicine at Mayo Clinic say it has to do with developing completely new ways to treat and manage chronic diseases such as diabetes, heart failure or even degenerative nerve, bone and joint conditions. Experts worldwide will meet this December for the World Stem Cell Summit, where they #39;ll explore and share ideas about regenerative medicine. Here are the basics of how this research benefits patients.From:mayoclinicViews:654 8ratingsTime:02:20More inScience Technology

Read the original:
Stem Cells 101 - Mayo Clinic - Video

Stem Cells for Regenerative Medicine
http://www.ucsf.edu Stem cell banks might one day be used to meet the tissue-transplant needs of most of the population. Just as there are universal blood donors, cells from universal donors could be used to develop induced pluripotent stem cells (iPS cells) or adult stem cells for use in repairing the nervous system, the heart or other organs. Off-the-shelf cell lines could be made available for recipients in a timely way, with matching likely to lower risk of transplant rejection. UCSF stem cell scientist Bruce Conklin, MD, discusses.From:UCSFPublicAffairsViews:20 1ratingsTime:03:29More inEducation

View original post here:
Stem Cells for Regenerative Medicine - Video

Stem Cells and Insurance
The current state of the economy is uncertain and cause for concern for any business. Stem cell banks are no exception. When banks close down for any reason, its customers are immediately outraged about the money they have deposited. In the event of a stem cell bank failure, the investment is much more precious. These cells are of great interest in research because of their immense potential in regenerative medicine and other applications. A contingency plan needs to be implemented in order to protect these resources that are being used to find valuable treatments for otherwise incurable diseases.From:Alexandra KellyViews:2 0ratingsTime:02:53More inPeople Blogs

Continued here:
Stem Cells and Insurance - Video

SCMOM 2012_Owl Biomedical
Owl biomedical is an emerging company commercializing an innovative high-speed, disposable cartridge-based cell sorting platform called the Nanosorter. The Nanosorter enables rapid processing of large numbers of cells safely without aerosols and in a simple, readily deployable and easy to use system. The Nanosorter platform uniquely combines the world #39;s fastest microvalve (fabricated within a microchip) and the well-proven principles of fluorescence-activated sorting of cells. Cells purified using the Nanosorter can be employed for a wide variety of commercial applications, including: adoptive immunotherapy for treatment of cancer, stem cell therapies for regenerative medicine (eg stroke, limb ischemia, wound healing), cell-based cancer diagnostics, and a wide variety of cell-based applied research applications. Owl biomedical was founded in 2011 and is based in Santa Barbara, California. http://www.owlbiomedical.com Presenter: Jim Linton, Ph.D., MBA, President and Chief Business Officer, Owl BiomedicalFrom:AllianceRegenMedViews:7 1ratingsTime:15:31More inScience Technology

Read the rest here:
SCMOM 2012_Owl Biomedical - Video